Human Microbiome Therapeutics Market Size, Share, Trends, Growth Outlook

Human Microbiome Therapeutics Market is estimated to increase at a growth rate of 32.8% CAGR over the forecast period from 2024 to 2030.

The global Human Microbiome Therapeutics Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Product (Probiotics, Prebiotics, Medical foods, Prescription drugs), By Application (Gastrointestinal disorders, Infectious diseases, Others).

An Introduction to Human Microbiome Therapeutics Market in 2024

The Human Microbiome Therapeutics Market involves the development, production, and commercialization of therapies targeting the human microbiome, which consists of trillions of microorganisms residing in and on the human body. These therapies include probiotics, prebiotics, synbiotics, and microbiome modulators designed to restore, balance, or modify the microbial communities in the gut, skin, and other body sites to improve health outcomes. The market focuses on addressing various conditions such as gastrointestinal disorders, metabolic syndromes, immune disorders, and dermatological conditions by leveraging the symbiotic relationship between the human host and its microbiota. Innovations in human microbiome therapeutics aim to enhance specificity, efficacy, safety, and personalized treatment approaches based on an individual's unique microbiome composition.

Human Microbiome Therapeutics Market Competitive Landscape

The global Human Microbiome Therapeutics Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Human Microbiome Therapeutics Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Human Microbiome Therapeutics Industry include- 4D pharma Plc, BiomX Inc, Eligo Bioscience, ENTEROME SA, Evelo Biosciences Inc, Evogene Ltd, Ferring BV, Finch Therapeutics Group Inc, Flightpath Biosciences, Johnson and Johnson Services Inc, Locus Biosciences Inc, MaaT Pharma, Microbiotica Ltd, OptiBiotix Health Plc, PureTech Health Plc, Second Genome Therapeutics, Seres Therapeutics Inc, Synlogic Inc, Takeda Pharmaceutical Co. Ltd, YSOPIA Bioscience.

Human Microbiome Therapeutics Market Trend: Rise in Research and Development of Microbiome-based Therapies

A significant trend in the Human Microbiome Therapeutics market is the increasing focus on research and development of microbiome-based therapies, driven by growing recognition of the microbiome's role in health and disease. Advances in microbiome science have revealed the intricate relationship between the human microbiota and various physiological processes, including immune regulation, metabolism, and neurobiology. Researchers and biopharmaceutical companies are exploring the therapeutic potential of manipulating the microbiome composition and activity to treat a wide range of conditions, such as gastrointestinal disorders, metabolic syndromes, and autoimmune diseases. With the emergence of microbiome-targeted drug candidates, including live biotherapeutic products (LBPs), microbial consortia, and microbiome modulators, the Human Microbiome Therapeutics market is witnessing a surge in investment, partnerships, and clinical development activities.

Human Microbiome Therapeutics Market Driver: Increasing Prevalence of Chronic Diseases and Antibiotic Resistance

The primary driver for the Human Microbiome Therapeutics market is the increasing prevalence of chronic diseases and antibiotic resistance, driving the need for novel therapeutic approaches that modulate the microbiome and restore microbial balance. Chronic conditions, such as inflammatory bowel disease (IBD), obesity, diabetes, and allergies, have been associated with dysbiosis, alterations in the gut microbiota composition, and microbial-driven inflammation. Additionally, the rise of antibiotic-resistant pathogens and the adverse effects of broad-spectrum antibiotics on the microbiome have highlighted the importance of developing microbiome-based alternatives for disease management and infection control. Human microbiome therapeutics offer potential solutions to address these challenges by restoring microbial diversity, enhancing host-microbe interactions, and promoting health-promoting microbial functions. As healthcare providers seek alternatives to conventional therapies and antibiotics, the demand for microbiome-targeted interventions is expected to drive market growth in the Human Microbiome Therapeutics segment.

Human Microbiome Therapeutics Market Opportunity: Expansion into Indications Beyond Gastrointestinal Disorders

An emerging opportunity in the Human Microbiome Therapeutics market lies in the expansion into therapeutic indications beyond gastrointestinal disorders, tapping into the broader potential of microbiome modulation in various disease areas. While the initial focus of microbiome therapeutics has been on gastrointestinal conditions, such as irritable bowel syndrome (IBS) and Clostridium difficile infection (CDI), emerging evidence suggests the involvement of the microbiome in other health conditions, including dermatological disorders, neurological diseases, and oncology. By exploring the role of the microbiome in systemic health and disease, researchers and biopharmaceutical companies can identify new therapeutic targets and develop microbiome-based interventions for diverse clinical applications. Furthermore, advancements in microbiome profiling technologies, bioinformatics, and personalized medicine approaches enable the characterization of patient-specific microbiome signatures and the development of targeted therapies tailored to individual microbial profiles. Collaborative efforts between academia, industry, and regulatory agencies are essential to advance research, clinical translation, and market adoption of microbiome therapeutics across a broad spectrum of disease indications, presenting opportunities for innovation and market expansion in the Human Microbiome Therapeutics segment.

Human Microbiome Therapeutics Market Share Analysis: Probiotics is the fastest growing market segment over the forecast period to 2030

Probiotics are live microorganisms that confer health benefits when consumed in adequate amounts, primarily by modulating the composition and activity of the gut microbiota. These beneficial bacteria, such as Lactobacillus and Bifidobacterium strains, have gained attention for their potential therapeutic applications in various health conditions. Probiotics are available in a variety of formulations, including capsules, tablets, yogurts, and fermented foods, making them accessible and convenient for consumers. The growing body of research supporting the role of the gut microbiome in health and disease has fueled the demand for probiotic products, particularly in the management of gastrointestinal disorders such as irritable bowel syndrome, inflammatory bowel disease, and diarrhea. Additionally, probiotics have shown promise in preventing and treating infectious diseases by enhancing the immune response and competing with pathogenic microorganisms for colonization in the gut. As a result, the Probiotics segment is emerging as the fastest-growing category in the human microbiome therapeutics market, offering a natural and evidence-based approach to promoting gut health and overall well-being.

Human Microbiome Therapeutics Market Segmentation

By Product
Probiotics
Prebiotics
Medical foods
Prescription drugs
By Application
Gastrointestinal disorders
Infectious diseases
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Human Microbiome Therapeutics Companies

4D pharma Plc
BiomX Inc
Eligo Bioscience
ENTEROME SA
Evelo Biosciences Inc
Evogene Ltd
Ferring BV
Finch Therapeutics Group Inc
Flightpath Biosciences
Johnson and Johnson Services Inc
Locus Biosciences Inc
MaaT Pharma
Microbiotica Ltd
OptiBiotix Health Plc
PureTech Health Plc
Second Genome Therapeutics
Seres Therapeutics Inc
Synlogic Inc
Takeda Pharmaceutical Co. Ltd
YSOPIA Bioscience
* List not Exhaustive

Reasons to Buy the Human Microbiome Therapeutics Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Human Microbiome Therapeutics Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Human Microbiome Therapeutics Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Human Microbiome Therapeutics Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Human Microbiome Therapeutics Market Size Outlook, $ Million, 2021 to 2030
3.2 Human Microbiome Therapeutics Market Outlook by Type, $ Million, 2021 to 2030
3.3 Human Microbiome Therapeutics Market Outlook by Product, $ Million, 2021 to 2030
3.4 Human Microbiome Therapeutics Market Outlook by Application, $ Million, 2021 to 2030
3.5 Human Microbiome Therapeutics Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Human Microbiome Therapeutics Industry
4.2 Key Market Trends in Human Microbiome Therapeutics Industry
4.3 Potential Opportunities in Human Microbiome Therapeutics Industry
4.4 Key Challenges in Human Microbiome Therapeutics Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Human Microbiome Therapeutics Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Human Microbiome Therapeutics Market Outlook by Segments
7.1 Human Microbiome Therapeutics Market Outlook by Segments, $ Million, 2021- 2030
By Product
Probiotics
Prebiotics
Medical foods
Prescription drugs
By Application
Gastrointestinal disorders
Infectious diseases
Others
8 North America Human Microbiome Therapeutics Market Analysis and Outlook To 2030
8.1 Introduction to North America Human Microbiome Therapeutics Markets in 2024
8.2 North America Human Microbiome Therapeutics Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Human Microbiome Therapeutics Market size Outlook by Segments, 2021-2030
By Product
Probiotics
Prebiotics
Medical foods
Prescription drugs
By Application
Gastrointestinal disorders
Infectious diseases
Others
9 Europe Human Microbiome Therapeutics Market Analysis and Outlook To 2030
9.1 Introduction to Europe Human Microbiome Therapeutics Markets in 2024
9.2 Europe Human Microbiome Therapeutics Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Human Microbiome Therapeutics Market Size Outlook by Segments, 2021-2030
By Product
Probiotics
Prebiotics
Medical foods
Prescription drugs
By Application
Gastrointestinal disorders
Infectious diseases
Others
10 Asia Pacific Human Microbiome Therapeutics Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Human Microbiome Therapeutics Markets in 2024
10.2 Asia Pacific Human Microbiome Therapeutics Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Human Microbiome Therapeutics Market size Outlook by Segments, 2021-2030
By Product
Probiotics
Prebiotics
Medical foods
Prescription drugs
By Application
Gastrointestinal disorders
Infectious diseases
Others
11 South America Human Microbiome Therapeutics Market Analysis and Outlook To 2030
11.1 Introduction to South America Human Microbiome Therapeutics Markets in 2024
11.2 South America Human Microbiome Therapeutics Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Human Microbiome Therapeutics Market size Outlook by Segments, 2021-2030
By Product
Probiotics
Prebiotics
Medical foods
Prescription drugs
By Application
Gastrointestinal disorders
Infectious diseases
Others
12 Middle East and Africa Human Microbiome Therapeutics Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Human Microbiome Therapeutics Markets in 2024
12.2 Middle East and Africa Human Microbiome Therapeutics Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Human Microbiome Therapeutics Market size Outlook by Segments, 2021-2030
By Product
Probiotics
Prebiotics
Medical foods
Prescription drugs
By Application
Gastrointestinal disorders
Infectious diseases
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
4D pharma Plc
BiomX Inc
Eligo Bioscience
ENTEROME SA
Evelo Biosciences Inc
Evogene Ltd
Ferring BV
Finch Therapeutics Group Inc
Flightpath Biosciences
Johnson and Johnson Services Inc
Locus Biosciences Inc
MaaT Pharma
Microbiotica Ltd
OptiBiotix Health Plc
PureTech Health Plc
Second Genome Therapeutics
Seres Therapeutics Inc
Synlogic Inc
Takeda Pharmaceutical Co. Ltd
YSOPIA Bioscience
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Product
Probiotics
Prebiotics
Medical foods
Prescription drugs
By Application
Gastrointestinal disorders
Infectious diseases
Others